Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FuFangCongRongYiZhiJiaoNang for prevention of cognitive impairment after stroke
ChiCTR-TRC-11001301Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of FuFangCongRongYiZhiJiaoNang and aspirin in vascular cognitive disorder (VCD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Montreal Cognitive Assessment and Mini-Mental State Examination. Started Jan 2010; status: completed.
02
Drugs
FuFangCongRongYiZhiJiaoNangaspirin
03
Conditions
vascular cognitive disorder (VCD)
Beyond the preview
Go deeper on ChiCTR-TRC-11001301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001301.